Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study
Neumora Therapeutics, Inc. has initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898, a M4 Positive Allosteric Modulator.
NMRA-898 is the second M4 PAM in Neumora's M4 franchise and has potential best-in-class pharmacology. It is structurally distinct from NMRA-861.
- No convulsions were observed in pre-clinical studies conducted in multiple species, including rabbits.
- Neumora plans to provide a comprehensive M4 franchise update by mid-2026.
No additional information is available at this time.
Author summary: Neumora starts Phase 1 study of NMRA-898.
More News
- £3.53 for The Traitors? The BBC licence fee is a bargain
- Stoke City vs Hull City; Sky Bet Championship
- THE 10 BEST Restaurants in Paris (Updated November 2025): Diverse Culinary Experiences and Top Local Favorites
- 🚨 La santé de Bruce Willis, 70 ans, est en train de décliner
- Avec l'abonnement Deliveroo Plus, ta livraison devient gratuite toute l'année
- Score top beauty Advent calendars from Sephora, Ulta, Macy's, more
- Cardinals vs. Buccaneers Final Score Prediction for NFL Week 13
- Why skipping lunch at work can hurt your health and productivity
- Championship: Sheff Utd lead Leicester 3-0
- The Original Victorious and Its Unexpected Ending